Endermologie Versus Negative Pressure Therapy on Postmastectomy Lymphedema

December 24, 2023 updated by: Rayda Maher Mohamed Abdelkhalek, Cairo University

Statement of the problem:

The problem will be stated in a questionary form:

"Which will be more effective endermologie or negative pressure therapy in reducing limb circumference and volume in postmastectomy lymphedema?".

Hypothesis:

It will be hypothesized that:

There is no significant difference between endermologie and negative pressure therapy in reducing circumference and limb volume in post mastectomy lymphedema.

Study Overview

Status

Completed

Detailed Description

Subject:

Sixty- eight women treated for unilateral breast cancer with secondary upper limb lymphedema post mastectomy will participate in this study. Their ages will be ranged from 40 to 60 years, they will be free from any other diseases that will affect or influence the results and the participants will be selected from National Cancer Institute and randomly distributed into two equal groups in number.

Study design:

In this study the patients will be randomly assigned into two groups equal in number (34 patients for each group).

Inclusion Criteria:

The subject selection will be according to the following criteria:

  • Only females will participate in the study.
  • Patients' age will be ranged between 40-60 years.
  • All patients will suffer from post mastectomy lymph-edema.
  • All patients have a modified radical mastectomy.
  • All patients will suffer from grade II lymph edema without skin changes one year post mastectomy.
  • All patients are right-dominant hand.
  • All patients enrolled to the study have their informed consent.

Exclusion Criteria:

The potential participants will be excluded if they meet one of the following criteria:

  • primary lymph-edema.
  • Diabetes mellitus.
  • Pregnancy.
  • Recurrent cancer.
  • Current or recent cellulitis.
  • Current metastases.
  • Venous thrombosis.
  • Photosensitivity.
  • Phlebitis in development stage.
  • Infection.
  • Receiving anti-coagulant treatment.

Equipment:

The study equipment's will be divided into measurement and therapeutic equipment and tools:

1: Measurement equipment

1(a):Limb volume measurement:

This will be performed by measuring the circumference of each segment of the limb between two consecutive circumferences as a truncated zone. The volume of the segment was calculated as:

V=h (c12+c1c2+c22 )/12π, where V is the volume of the segment, c1 and c2 are the circumferences at the ends of the segment, and h is the distance between them.

Measurement of limb volume measurement will be conducted pre-treatment and after treatment course (6 weeks).

  1. (b): Measuring Disability of the arm, shoulder and hand by: .Quick DASH questionnaire (Disability of the arm, shoulder, and hand).

    • The Quick- DASH has five response options for each item from 0=no difficulty to perform or no symptoms to 5=unable to do.
    • Quick DASH scale will be conducted pre-treatment and after treatment course (6 weeks).
  2. Therapeutic equipment :

2. a. Endermologie: endermologie therapy will be three sessions per week for six weeks (total 18 sessions).

The study group will receive 18 sessions by Endermologie system ( used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.

Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.

2.b. Negative pressure therapy:

  • Pressure: 20-250 mm Hg.
  • Total treatment period: six weeks.
  • A number of sessions: 3 sessions/ week. Time of application : 30 min

Study Type

Interventional

Enrollment (Actual)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Dokki
      • Giza, Dokki, Egypt, 11432
        • Outpatient Clinic, Faculty of Physical Therapy, Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Only females will participate in the study.
  • Patients' age was ranged between 40-60 years.
  • All patients will suffer from post mastectomy lymphedema.
  • All patients have a modified radical mastectomy.
  • All patients suffer from grade II lymphedema without skin changes one year post mastectomy(as defined by the International Society of Lymphology).
  • All patients are right-dominant hand.
  • All patients enrolled to the study will have their informed consent.

Exclusion Criteria:

  • The potential participants will be excluded if they meet one of the following criteria:

    • primary lymphedema.
    • Diabetes mellitus.
    • Pregnancy.
    • Recurrent cancer.
    • Current or recent cellulitis.
    • Current metastases.
    • Venous thrombosis.
    • Photosensitivity.
    • Phlebitis in development stage.
    • Infection.
    • Receiving anti-coagulant treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A (endermologie group)
This group includes 34 patients who will receive 30 min Endermologie 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks.

Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.

Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.

-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

Experimental: Group B (Negative pressure therapy group)
This group includes34 patients who will receive 30min negative pressure therapy 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks

Group B will receive negative pressure therapy with

  • Pressure: 20-250 mmHg.
  • Total treatment period: 6weeks
  • A number of sessions: 3sessions/ week. Time of application : 30 min
  • In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measuring Disability of the arm, shoulder and hand
Time Frame: Measuring will be taken before treatment and after 6 weeks of treatment to monitor the change in upper limb function before and after treatment
Measuring Disability of the arm, shoulder and hand will be carried out by using Quick-DASH questionnaire
Measuring will be taken before treatment and after 6 weeks of treatment to monitor the change in upper limb function before and after treatment
Limb volume measurement
Time Frame: Measuring will be taken before treatment and after 6 weeks of treatment to monitor the change in upper limb volume and decrease of lymph-edema

Limb volume measurement will be carried out by by measuring the circumference of each segment of the limb between two consecutive circumferences as a truncated zone. The volume of the segment was calculated as:

V=h (c1+c1c2+c2 )/12π

Measuring will be taken before treatment and after 6 weeks of treatment to monitor the change in upper limb volume and decrease of lymph-edema

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rayda M Mohamed, Cairo Unversity

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 29, 2022

Primary Completion (Actual)

June 1, 2023

Study Completion (Actual)

October 30, 2023

Study Registration Dates

First Submitted

February 13, 2023

First Submitted That Met QC Criteria

March 7, 2023

First Posted (Actual)

March 9, 2023

Study Record Updates

Last Update Posted (Actual)

December 27, 2023

Last Update Submitted That Met QC Criteria

December 24, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • P.T.REC/012/003744

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mastectomy; Lymphedema

Subscribe